Moderna, Inc. (MRNA) shares were up over 3% in choppy trading on Friday afternoon, even as the biotech firm reported a ...

The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Moderna’s consensus price target has significantly declined from $119.26 to $47.5, indicating a cautious outlook from ...

Moderna Inc.’s stock fell 3% early Friday, after the biotech posted a wider-than-expected fourth-quarter loss and offered ...

Moderna reported a Q4 EPS loss of $2.91, missing estimates, with revenue down 66% YoY to $966 million. The company reaffirmed ...

Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...

Moderna reported mixed fourth quarter earnings, and full year 2024 earnings compared to Wall Street expectations Friday.

Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...